Literature DB >> 26174939

Improving Health Education for Women Who Carry an FMR1 Premutation.

Whitney Espinel1,2, Krista Charen3, Lillie Huddleston4, Jeannie Visootsak3, Stephanie Sherman3.   

Abstract

Women who carry an FMR1 (i.e., fragile X) premutation have specific health risks over their lifetime. However, little is known about their experience understanding these risks and navigating their health needs. The aim of this study was to use qualitative analysis to uncover both barriers and facilitators to personal healthcare using a framework of the Health Belief Model. Five focus groups were conducted with a total of 20 women who carry the FMR1 premutation using a semi-structured discussion guide. All sessions were transcribed verbatim and independently coded by two researchers. The coders used a deductive - inductive approach to determine the prominent themes related to the participants' experiences seeking healthcare for premutation-related conditions. Salient barriers to personal healthcare included difficult clinical translation of research findings, lack of knowledge among healthcare providers and among the women themselves, different priorities, and shortage of premutation-specific support and targeted educational materials. Facilitators included family members, national and community support organizations, research studies, compassionate physicians, and other premutation carriers. Addressing barriers to personal healthcare through up-to-date educational materials can help diminish misperceptions regarding health risks. Targeted educational materials will aid in information sharing and awareness for women who carry the FMR1 premutation and their physicians.

Entities:  

Keywords:  Barriers; Educational materials; FMR1 premutation; Facilitators; Focus groups; Fragile X associated disorders; Health Belief Model; Health education; Qualitative analysis

Mesh:

Substances:

Year:  2015        PMID: 26174939      PMCID: PMC4831205          DOI: 10.1007/s10897-015-9862-4

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  39 in total

1.  Assessing the emotional needs of women with spontaneous premature ovarian failure.

Authors:  Allison A Groff; Sharon N Covington; Lynn R Halverson; O Ray Fitzgerald; Vien Vanderhoof; Karim Calis; Lawrence M Nelson
Journal:  Fertil Steril       Date:  2005-06       Impact factor: 7.329

2.  High rates of comorbid depressive and anxiety disorders among women with premutation of the FMR1 gene.

Authors:  Heather A Kenna; Molly Tartter; Scott S Hall; Amy A Lightbody; Quynh Nguyen; C Paula de los Angeles; Allan L Reiss; Natalie L Rasgon
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2013-09-03       Impact factor: 3.568

3.  Women's knowledge about menopause, hormone replacement therapy (HRT), and interactions with healthcare providers: an exploratory study.

Authors:  C Clinkingbeard; B A Minton; J Davis; K McDermott
Journal:  J Womens Health Gend Based Med       Date:  1999-10

Review 4.  Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.

Authors:  Jenny A Visser; Izaäk Schipper; Joop S E Laven; Axel P N Themmen
Journal:  Nat Rev Endocrinol       Date:  2012-01-10       Impact factor: 43.330

5.  Association of FMR1 repeat size with ovarian dysfunction.

Authors:  A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

6.  Expanded clinical phenotype of women with the FMR1 premutation.

Authors:  Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2008-04-15       Impact factor: 2.802

7.  Examination of reproductive aging milestones among women who carry the FMR1 premutation.

Authors:  E G Allen; A K Sullivan; M Marcus; C Small; C Dominguez; M P Epstein; K Charen; W He; K C Taylor; S L Sherman
Journal:  Hum Reprod       Date:  2007-06-22       Impact factor: 6.918

8.  Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis.

Authors:  Amy Cronister; Jennifer Teicher; Elizabeth M Rohlfs; Alan Donnenfeld; Stephanie Hallam
Journal:  Obstet Gynecol       Date:  2008-03       Impact factor: 7.661

9.  Fragile X full mutation expansions are inhibited by one or more AGG interruptions in premutation carriers.

Authors:  Sarah L Nolin; Anne Glicksman; Nicole Ersalesi; Carl Dobkin; W Ted Brown; Ru Cao; Eliot Blatt; Sachin Sah; Gary J Latham; Andrew G Hadd
Journal:  Genet Med       Date:  2014-09-11       Impact factor: 8.822

Review 10.  Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems.

Authors:  Randi J Hagerman; Deborah A Hall; Sarah Coffey; Maureen Leehey; James Bourgeois; John Gould; Lin Zhang; Andreea Seritan; Elizabeth Berry-Kravis; John Olichney; Joshua W Miller; Amy L Fong; Randall Carpenter; Cathy Bodine; Louise W Gane; Edgar Rainin; Hillary Hagerman; Paul J Hagerman
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more
  3 in total

1.  Health knowledge of women with a fragile X premutation: Improving understanding with targeted educational material.

Authors:  Liana Smolich; Krista Charen; Stephanie L Sherman
Journal:  J Genet Couns       Date:  2020-01-30       Impact factor: 2.537

2.  Men with an FMR1 premutation and their health education needs.

Authors:  Matthew B Walsh; Krista Charen; Lisa Shubeck; Allyn McConkie-Rosell; Nadia Ali; Cecelia Bellcross; Stephanie L Sherman
Journal:  J Genet Couns       Date:  2021-03-31       Impact factor: 2.717

3.  Refining the risk for fragile X-associated primary ovarian insufficiency (FXPOI) by FMR1 CGG repeat size.

Authors:  Emily Graves Allen; Krista Charen; Heather S Hipp; Lisa Shubeck; Ashima Amin; Weiya He; Sarah L Nolin; Anne Glicksman; Nicole Tortora; Bonnie McKinnon; Katharine E Shelly; Stephanie L Sherman
Journal:  Genet Med       Date:  2021-04-29       Impact factor: 8.822

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.